June 18, 2025—BioMérieux will acquire Day Zero Diagnostics, an infectious disease diagnostics company, with the aim of enhancing BioMérieux’s capabilities in next-generation sequencing and rapid diagnostics. Day Zero Diagnostics, based in Watertown, Mass., has developed technologies that integrate direct from whole blood sample preparation, sequencing, and advanced infectious disease and antimicrobial susceptibility testing analytics. The sequencing-based rapid diagnostic in development can identify the species and antibiotic resistance profile of a bacterial pathogen within hours.
The assets to be acquired include NGS workflows, chemistries, reagents, and the bioinformatics pipeline and software.